FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113669808> ?p ?o ?g. }

• W2113669808 endingPage "839" @default.
• W2113669808 startingPage "835" @default.
• W2113669808 abstract "To determine the effectiveness of a vitamin D analog, 1alpha-hydroxyvitamin D(2) (1alpha-OH-D(2)), in inhibiting retinoblastoma in a transgenic retinoblastoma model (LHbeta-Tag mouse) and to evaluate its toxicity.Experimental study using an animal (LHbeta-Tag transgenic mouse) randomized (controlled) trial.Two hundred seventeen LHbeta-Tag transgene-positive 8- to 10-week-old mice total; 179 drug-treated animals, 38 control animals.Mice were fed a vitamin D- and calcium-restricted diet and were randomized to treatment groups receiving control (vehicle), or 0.1, 0.3, 0.5, or 1.0 micro g/day of 1alpha-OH-D(2) via oral gavage 5 times weekly for 5 weeks. Body weight was measured at the start of treatment and twice weekly during treatment. Animals were euthanized on the last day of treatment. The eyes were enucleated, processed histologically, and serially sectioned. Representative sections from the superior, middle, and inferior regions of each globe were examined microscopically and tumor areas were measured using Optimas software. Serum was collected for serum calcium levels. Kidneys were removed for histologic processing and were analyzed microscopically for kidney calcification.Mean tumor area was measured to determine drug effectiveness. Toxicity was assessed by survival, weight loss over the treatment period, serum calcium, and kidney calcification.The mean tumor size in each 1alpha-OH-D(2) group was smaller than controls (all P values < 0.02): control, 90,248 micro m(2); 0.1 micro g, 31,545 micro m(2); 0.3 micro g, 16,750 micro m(2); 0.5 micro g, 30,245 micro m(2); and 1.0 micro g, 16,049 micro m(2). No dose-dependent response curve was evident. The survival percentage for each group was as follows: control, 97%; 0.1 micro g, 91%; 0.3 micro g, 88%; 0.5 micro g, 70%; and 1.0 micro g, 63%. Mortality was higher in the 0.5- micro g and 1.0- micro g doses (P values < 0.01) compared with other treatment groups and with the control group. Serum calcium levels were significant in all treatment groups compared with controls (all P values < 0.0001).In the LHbeta-Tag mouse, 1alpha-OH-D(2) inhibits retinoblastoma with no significant increase in mortality in lower doses (0.1-0.3 micro g). 1alpha-OH-D(2) has approval by the Food and Drug Administration as an investigative drug for cancer treatment, and has shown efficacy with low toxicity in adult cancer trials. 1alpha-OH-D(2) meets the criteria for human clinical trials." @default.
• W2113669808 created "2016-06-24" @default.
• W2113669808 creator A5013334434 @default.
• W2113669808 creator A5033534773 @default.
• W2113669808 creator A5040257835 @default.
• W2113669808 creator A5041077774 @default.
• W2113669808 creator A5058832286 @default.
• W2113669808 creator A5063968197 @default.
• W2113669808 creator A5075174785 @default.
• W2113669808 date "2003-04-01" @default.
• W2113669808 modified "2023-10-12" @default.
• W2113669808 title "Toxicity and dose-response studies of 1-α hydroxyvitamin D2 in LH-β-tag transgenic mice" @default.
• W2113669808 cites W117680770 @default.
• W2113669808 cites W1973757037 @default.
• W2113669808 cites W2008934394 @default.
• W2113669808 cites W2014508206 @default.
• W2113669808 cites W2060063916 @default.
• W2113669808 cites W2073153937 @default.
• W2113669808 cites W2085679942 @default.
• W2113669808 cites W2122036732 @default.
• W2113669808 cites W2126916263 @default.
• W2113669808 cites W2128880567 @default.
• W2113669808 cites W2160392074 @default.
• W2113669808 cites W2166961563 @default.
• W2113669808 doi "https://doi.org/10.1016/s0161-6420(02)01934-6" @default.
• W2113669808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12689912" @default.
• W2113669808 hasPublicationYear "2003" @default.
• W2113669808 type Work @default.
• W2113669808 sameAs 2113669808 @default.
• W2113669808 citedByCount "17" @default.
• W2113669808 countsByYear W21136698082012 @default.
• W2113669808 countsByYear W21136698082015 @default.
• W2113669808 countsByYear W21136698082018 @default.
• W2113669808 crossrefType "journal-article" @default.
• W2113669808 hasAuthorship W2113669808A5013334434 @default.
• W2113669808 hasAuthorship W2113669808A5033534773 @default.
• W2113669808 hasAuthorship W2113669808A5040257835 @default.
• W2113669808 hasAuthorship W2113669808A5041077774 @default.
• W2113669808 hasAuthorship W2113669808A5058832286 @default.
• W2113669808 hasAuthorship W2113669808A5063968197 @default.
• W2113669808 hasAuthorship W2113669808A5075174785 @default.
• W2113669808 hasConcept C102230213 @default.
• W2113669808 hasConcept C104317684 @default.
• W2113669808 hasConcept C124490489 @default.
• W2113669808 hasConcept C126322002 @default.
• W2113669808 hasConcept C134018914 @default.
• W2113669808 hasConcept C141035611 @default.
• W2113669808 hasConcept C2776577112 @default.
• W2113669808 hasConcept C2780091579 @default.
• W2113669808 hasConcept C2780309369 @default.
• W2113669808 hasConcept C29730261 @default.
• W2113669808 hasConcept C519063684 @default.
• W2113669808 hasConcept C55493867 @default.
• W2113669808 hasConcept C71924100 @default.
• W2113669808 hasConcept C86803240 @default.
• W2113669808 hasConceptScore W2113669808C102230213 @default.
• W2113669808 hasConceptScore W2113669808C104317684 @default.
• W2113669808 hasConceptScore W2113669808C124490489 @default.
• W2113669808 hasConceptScore W2113669808C126322002 @default.
• W2113669808 hasConceptScore W2113669808C134018914 @default.
• W2113669808 hasConceptScore W2113669808C141035611 @default.
• W2113669808 hasConceptScore W2113669808C2776577112 @default.
• W2113669808 hasConceptScore W2113669808C2780091579 @default.
• W2113669808 hasConceptScore W2113669808C2780309369 @default.
• W2113669808 hasConceptScore W2113669808C29730261 @default.
• W2113669808 hasConceptScore W2113669808C519063684 @default.
• W2113669808 hasConceptScore W2113669808C55493867 @default.
• W2113669808 hasConceptScore W2113669808C71924100 @default.
• W2113669808 hasConceptScore W2113669808C86803240 @default.
• W2113669808 hasIssue "4" @default.
• W2113669808 hasLocation W21136698081 @default.
• W2113669808 hasLocation W21136698082 @default.
• W2113669808 hasOpenAccess W2113669808 @default.
• W2113669808 hasPrimaryLocation W21136698081 @default.
• W2113669808 hasRelatedWork W2003842308 @default.
• W2113669808 hasRelatedWork W2018690794 @default.
• W2113669808 hasRelatedWork W2024618244 @default.
• W2113669808 hasRelatedWork W2025590009 @default.
• W2113669808 hasRelatedWork W2064236298 @default.
• W2113669808 hasRelatedWork W2095093072 @default.
• W2113669808 hasRelatedWork W2104791454 @default.
• W2113669808 hasRelatedWork W2122395778 @default.
• W2113669808 hasRelatedWork W2127085070 @default.
• W2113669808 hasRelatedWork W4248381333 @default.
• W2113669808 hasVolume "110" @default.
• W2113669808 isParatext "false" @default.
• W2113669808 isRetracted "false" @default.
• W2113669808 magId "2113669808" @default.
• W2113669808 workType "article" @default.